



PATIENT INFORMATION

^[1] Patient Name _____ ^[2] Date of Birth _____ ^[3] Height _____ ^[4] Weight _____

^[5] Patient Address _____ ^[6] Patient Telephone # _____ ^[7] Patient Mobile # _____

^[8] Referring Provider _____ ^[9] Provider Telephone # _____ ^[10] Provider Fax# _____

^[11] SIGNS AND SYMPTOMS (REQUIRED)

Type of cancer _____ Histologically Proven Suspected

CPT Codes

If provided a specific CPT code, please provide.

Please check Radiopharmaceutical

FDG NETSPOT@Ga68 Axumin

INSURANCE INFORMATION

^[12] Primary Insurance _____ ^[13] Subscribers Insurance ID # _____

Secondary Insurance _____ Insurance Prior Authorization # _____

CMS/APPROPRIATE USE CRITERIA (FOR MEDICARE PART B PATIENTS ONLY)

NPI# _____ Name of CDSM Consulted (software used) _____ **Determination Result (check one):**
 1) Adheres to 2) Does Not Adhere to 3) Not Applicable

^[15] (Check ONE and fill out corresponding section completely)

Initial Treatment Strategy

Diagnosis: Abnormal finding of _____
Based on _____

Check one

To determine whether the patient is a candidate for an invasive diagnosis or therapeutic procedure;

To determine the optimal anatomic location for an invasive procedure; or

To determine the anatomic extent of the tumor when the treatment recommendations depend on the extent,

Initial Staging: of confirmed newly diagnosed cancer

Check one

To determine whether the patient is a candidate for an invasive diagnosis or therapeutic procedure;

To determine the optimal anatomic location for an invasive procedure; or

To determine the anatomic extent of the tumor when the treatment recommendations depend on the extent.

Other (e.g., Alzheimer's Disease). Please list reason for scan here:

Subsequent Treatment Strategy

Restaging: (after the completion of treatment)

Check one

Status post the completion of treatment for the purpose of detecting residual disease
Last date of treatment: _____
Type of treatment: _____

Detecting suspected recurrence, or metastasis of previously treated cancer:
Site of suspected recurrence / metastasis: _____
Based on: _____

Determine the extent of a known recurrence.
Confirmed by: _____

PET/CT is being used to potentially replace one or more imaging studies that (1) is being utilized to determine extent of known recurrence of (2) provided insufficient information for the clinical management of the patient.

Monitoring Tumor Response: During Treatment

Check one

Chemotherapy Radiotherapy Other (specify): _____

^[16] PRESCREENING QUESTIONNAIRE

Prior Studies/Treatment

Pregnant: Y N Previous: CT MRI PET/CT Where: _____ When: _____

Diabetes: Y N Pathology: Y N Where: _____ When: _____

Radiation Therapy: Y N Provider: _____ When: _____

Chemotherapy: Y N Provider: _____ When: _____

^[17] Authorized Treating Provider's Signature: (Stamps Not Accepted) _____ ^[18] NPI # _____ ^[19] Date _____

Services provided by



Please FAX this form (and recent office notes, radiology reports and pathology reports) to our Scheduling Department after patient's examination has been scheduled.